Canopy Growth Corporation
CGC Healthcare Drug Manufacturers Specialty & Generic
Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025. In the quarter to June 2026, revenue grew 12.4%, EPS grew 87.5%, free cash flow fell 117.6% and total debt fell 18.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, operating cash flow growth for three.
Follow CGC
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more TTM periods Free account |
199.33 | 199.41 | 206.00 | 212.47 |
Cost of Revenue |
146.08 | 147.97 | 155.57 | 159.02 | |
Gross Profit |
53.25 | 51.44 | 50.43 | 53.45 | |
SG&A Expenses |
101.68 | 100.88 | 118.88 | 121.44 | |
Operating Income |
(57.87) | (59.75) | (117.01) | (116.62) | |
Non-operating Income/Expense |
(215.97) | (171.90) | (73.27) | (54.46) | |
| (273.83) | (231.66) | (190.28) | (171.09) | ||
Income Tax Provision |
0.75 | 0.79 | 0.02 | (0.29) | |
Income after Tax |
(274.58) | (232.45) | (190.29) | (170.80) | |
Net Income Common |
(274.14) | (232.00) | (190.29) | (170.80) | |
EPS (Basic) |
(1.95) | (1.29) | (0.58) | (0.44) | |
EPS (Diluted) |
(1.95) | (1.29) | (0.58) | (0.44) | |
Shares (Basic, Weighted) |
170.05 | 228.86 | 276.48 | 334.97 | |
Shares (Diluted, Weighted) |
170.05 | 228.86 | 276.48 | 334.97 | |
Gross Margin |
26.71% | 25.80% | 24.48% | 25.16% | |
EBIT Margin |
(29.03%) | (29.97%) | (56.80%) | (54.89%) | |
EBT margin |
(137.37%) | (116.17%) | (92.37%) | (80.52%) | |
Net Profit Margin |
(137.53%) | (116.35%) | (92.38%) | (80.39%) | |
Free Cash Flow Margin |
(34.01%) | (31.52%) | (24.51%) | (28.34%) | |
EBITDA |
(28.79) | (31.41) | (90.61) | (89.97) | |
EBIT |
(57.87) | (59.75) | (117.01) | (116.62) | |
EPS (Diluted, from Cont. Ops) |
(1.90) | (1.24) | (0.64) | (0.50) | |
EPS (Diluted, Consolidated) |
(1.90) | (1.25) | (0.64) | (0.50) | |
EPS (Basic, Consolidated) |
(1.90) | (1.25) | (0.64) | (0.50) | |
Shares (Diluted, Average) |
181.80 | 240.61 | 298.22 | 356.70 | |
EPS (Basic, from Continuous Ops) |
(1.90) | (1.24) | (0.64) | (0.50) | |
Income from Continuous Operations |
(274.58) | (232.45) | (190.29) | (170.80) | |
Consolidated Net Income/Loss |
(274.14) | (232.00) | (190.29) | (170.80) | |
EBITDA Margin |
(14.44%) | (15.75%) | (43.99%) | (42.34%) | |
Operating Cash Flow Margin |
(31.23%) | (28.63%) | (22.42%) | (26.72%) |